Exagen Förvaltning
Förvaltning kriterier kontrolleras 1/4
Exagen VD är John Aballi, utsedd i Oct 2022, har en mandatperiod på 3.5 år. totala årliga ersättningen är $ 1.40M, bestående av 38.5% lön 61.5% bonusar, inklusive företagsaktier och optioner. äger direkt 1.96% av företagets aktier, värda $ 1.30M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.6 år respektive 4.8 år.
Viktig information
John Aballi
Verkställande direktör
US$1.4m
Total ersättning
| VD-lön i procent | 38.55% |
| Anställning som VD | 3.5yrs |
| Ägande av VD | 2.0% |
| Ledningens genomsnittliga anställningstid | 1.6yrs |
| Styrelsens genomsnittliga mandatperiod | 4.8yrs |
Senaste uppdateringar av ledningen
Recent updates
XGN: Volume Strength And 2026 Guidance Should Support Future Share Gains
Narrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.XGN: Shares Should Rise As Volumes Offset Transitory Pricing Headwinds
Analysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.XGN: Shares Should Rise As Volumes Support Long Term Margin Recovery
Analysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing Headwinds
The analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish Outlook
Narrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen Outlook
Analysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%
Jan 14
XGN: Shares Will Rise As 2025 Guidance Supports Profitability Milestone
The updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability Prospects
Analysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.Is Exagen (NASDAQ:XGN) Using Debt Sensibly?
Dec 18XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside Potential
Analysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.XGN: Shares Will Gain As Buy Ratings Signal 50% Upside Potential
Analysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%
Nov 18Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43
Nov 07XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside Potential
Analysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic Portfolio
Analysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now
Sep 13Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Aug 05Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 01Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The Industry
May 18Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75
May 09Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Apr 26
Biomarker Launch And AVISE CTD Expansion Will Drive Future Success
New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price Rise
Apr 03Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
Mar 04Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Feb 05Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 22Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Sep 06Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Aug 07Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
Jul 13Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
May 21Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Mar 26Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Mar 22Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
Jul 21Exagen appoints John Aballi as CEO
Oct 17Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Aug 10Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
Jul 26Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Apr 05Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Aug 06Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | US$1m | US$540k | -US$20m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$17m |
| Mar 31 2025 | n/a | n/a | -US$16m |
| Dec 31 2024 | US$1m | US$525k | -US$15m |
| Sep 30 2024 | n/a | n/a | -US$17m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$932k | US$525k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$35m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$1m | US$111k | -US$47m |
Ersättning vs marknad: John s total kompensation ($USD 1.40M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 629.02K ).
Ersättning vs inkomst: Ersättningen för John har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
John Aballi (40 yo)
3.5yrs
Anställning
US$1,400,868
Kompensation
Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. He...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Executive Chairman of the Board of Directors | 6.8yrs | US$198.18k | 0.22% $ 149.3k | |
| CEO, President & Director | 3.5yrs | US$1.40m | 1.96% $ 1.3m | |
| CFO & Corporate Secretary | 1.6yrs | US$746.19k | 0.37% $ 245.5k | |
| Chief Scientific Officer | less than a year | inga uppgifter | inga uppgifter | |
| Vice President of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Chief Medical Officer | less than a year | inga uppgifter | inga uppgifter |
1.6yrs
Genomsnittlig anställningstid
56yo
Genomsnittlig ålder
Erfaren ledning: XGN s ledningsgrupp anses inte vara erfaren ( 1.6 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Executive Chairman of the Board of Directors | 6.8yrs | US$198.18k | 0.22% $ 149.3k | |
| CEO, President & Director | 3.5yrs | US$1.40m | 1.96% $ 1.3m | |
| Member of Breast Cancer Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Breast Cancer Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Breast Cancer Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Breast Cancer Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Breast Cancer Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Breast Cancer Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | less than a year | US$87.60k | inga uppgifter | |
| Chairman of Scientific Advisory Board | 6.3yrs | US$130.00k | inga uppgifter | |
| Independent Director | 4.8yrs | US$126.29k | 0.14% $ 91.1k |
4.8yrs
Genomsnittlig anställningstid
61.5yo
Genomsnittlig ålder
Erfaren styrelse: XGN s styrelse anses vara erfaren ( 4.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 13:15 |
| Aktiekurs vid dagens slut | 2026/04/30 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Exagen Inc. bevakas av 7 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |